Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 235,682 |
|
|||||
| News | - | ||||||
| Day High | 3.55 | Low High |
|||||
| Day Low | 2.99 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Galectin Therapeutics Inc | GALT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.32 | 10.46% | 3.38 | 19:15:41 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.99 | 2.99 | 3.55 | 3.38 | 3.06 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,153 | 235,682 | $ 3.26 | $ 769,223 | - | 1.28 - 4.2684 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:35:53 | 50 | $ 3.35 | USD |
Galectin Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 208.43M | 61.85M | - | 0 | -44.81M | -0.72 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Galectin Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GALT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.87 | 3.87 | 2.88 | 3.30 | 233,520 | -0.49 | -12.66% |
| 1 Month | 2.36 | 4.2684 | 2.26 | 3.53 | 301,528 | 1.02 | 43.22% |
| 3 Months | 1.78 | 4.2684 | 1.59 | 3.00 | 152,095 | 1.60 | 89.89% |
| 6 Months | 2.02 | 4.2684 | 1.555 | 2.62 | 103,950 | 1.36 | 67.33% |
| 1 Year | 1.92 | 4.2684 | 1.28 | 2.29 | 79,827 | 1.46 | 76.04% |
| 3 Years | 3.39 | 5.70 | 1.02 | 3.24 | 338,605 | -0.01 | -0.29% |
| 5 Years | 4.19 | 5.70 | 1.02 | 3.04 | 400,574 | -0.81 | -19.33% |
Galectin Therapeutics Description
| Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis. |
